

PATENT Attorney Docket No. INE 109

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Robin Riyadh Gibson, et al.

Serial No.: 09/980,641

Filed: November 15, 2001

Examiner:

Art Unit:

For: PRODUCTION OF 1,1,1,2,3,3,3-

HEPTAFLUOROPROPANE

Commissioner for Patents Washington, D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, D.C. 20231 on:

April 15, 2002

Christine A. Barglik

Date: April 15, 2002

TECEIVED TO 1700

INFORMATION DISCLOSURE STATEMENT

De'ar Sir:

Pursuant to 37 C.F.R. §1.97, as revised on February 4, 1992, 1135 OG 23-24, Applicants hereby call the Examiner's attention to documents listed on the attached form, which documents may be material to the examination of this application.

No inference should be drawn that any apparatus disclosed is equivalent to the subject invention. Also, the citation of the above-discussed documents is not to be construed as an assertion that more pertinent art could not possibly be in existence. Citation of any document herein is not to be construed as an admission that any subject matter disclosed in the document is necessarily within the inventive field of endeavor, that any disclosure is necessarily prior in time to a particular date which

may be relevant to the instant patent application, and/or that any disclosure is otherwise necessarily prior art with respect to the instant invention.

Applicants also respectfully reserve the right to later set forth how the instant invention is distinguished over the disclosure of any document or other art, including the disclosure of those documents discussed herein, that may be cited by the Examiner in rejecting a claim in the present patent application.

Please note that U.S. Patent Nos. 4,158,023, 5,276,225 and 6,118,033 are U.S. counterparts of EP 509,885, DE 2712732 and PCT 97/11042, respectively, cited in the International Search Report and/or identified in the application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Accordingly, it is believed that no fee under 37 CFR 1.97(c) is required. If it is determined that a fee is required for this Information Disclosure Statement, please charge our Deposit Account No. 50/1039.

Respectfully submitted,

Andrew G. Kolomayets Attorney of Record

Registration No.: 33,723

COOK, ALEX, McFARRON, MANZO, CUMMINGS & MEHLER, LTD. 200 West Adams Street, Suite 2850 Chicago, Illinois 60606 (312)236-8500

Please type a plus sign (+) inside this box APR 2 2 2000 Under the Paperwork Reduction Act of 1995, no personal required to res	U.S. Patent and Tradema	PTO/SB/08A (08-00 ed for use through 10/31/2002. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE n unless it contains a valid OMB control number.
Substitute for form 1449A/PTO	c	mplete if Kn wn
	Application Number	09/980,641
INFORMATION DISCLOSURE	Filing Date	November 15, 2001
STATEMENT BY APPLICANT	First Named Inventor	Robin Riyadh Gibson, et al.
	Group Art Unit	
(use as many sheets as necessary)	Examiner Name	

Attorney Docket Number

ICI 109

				U.S. PATENT DOC	JMENTS		
Examiner Initials	Cite No.1	U.S. Patent Document Number Kind Code² (if known)		Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant	
	1	4,158,023	(II KNOWN)	von Halasz	06/12/1979	Figures Appear	
	2	5,276,225		Berthe	01/04/1994		
	3	6,118,033		Hopp et al.	09/12/2000		
		,				~ `C\	
		,				- (B)//	
		-					
						- T- 1072	
					+		
-		 					
					1		
\longrightarrow							
\longrightarrow							
- 1		l			1 1		

FOREIGN PATENT DOCUMENTS								
Examiner Cite Initials No.1	0.1	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	T
		Office	3 Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T6
	4	GB	902,590		Allied Chemical Corporation	08/01/1962		
	5	PCT	WO 96/00243		Exxon Chemical Patents, Inc.	01/04/1996		T
	6	PCT	WO 97/11042	A1	Solvay	03/27/1997		
	7	PCT	WO 99/26907 .	A1	Imperial Chemical Industries	06/03/1999		T
	8	PCT	WO 99/51555	A1	E. I. DuPont DeNemours & Co	10/14/1999		
	9	EPO	PCT/GB 00/01861		Imperial Chemical Industries	10/16/2000		Т
	10	EPO	PCT/GB00/01861		Imperial Chemical Industries	12/22/2000		\top
	11	EPO	PCT/GB00/01861		Ineos Fluor Holdings Limited	07/13/2001		T

Examiner	Date
Signature	Considered
	and the second s

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Sheet

of

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.